TY - JOUR
T1 - Therapeutic Potential of Ferulic Acid in Alzheimer's Disease
AU - Turkez, Hasan
AU - Arslan, Mehmet Enes
AU - Barboza, Joice Nascimento
AU - Kahraman, Cigdem Yuce
AU - de Sousa, Damiao Pergentino
AU - Mardinoğlu, Adil
N1 - Publisher Copyright:
© 2022 Bentham Science Publishers.
PY - 2022/2/10
Y1 - 2022/2/10
N2 - Alzheimer's Disease (AD) is one of the most important neurodegenerative diseases, ac-counting for 60% of all dementia cases. AD is a progressive neurodegenerative disease that occurs due to the production of β-amyloid (Aβ) protein and accumulation of hyper-phosphorylated tau pro-tein; it causes breakage in the synaptic bonds and neuronal deaths to a large extent. Millions of people worldwide suffer from AD because there is no definitive drug for disease prevention, treatment, or slowing down its progression. Over the last decade, multiple target applications have been devel-oped for AD treatments. These targets include Aβ accumulations, hyper-phosphorylated tau pro-teins, mitochondrial dysfunction, and oxidative stress, resulting in toxicity. Various natural or semisynthetic antioxidant formulations have been shown to protect brain cells from Aβ-induced toxicity and provide promising potentials for AD treatment. Ferulic acid (FA), a high-capacity an-tioxidant molecule, is naturally synthesized from certain plants. FA has been shown to have different substantial biological properties, such as anticancer, antidiabetic, antimicrobial, anti-inflamma-tory, hepatoprotective, and cardioprotective actions, etc. Furthermore, FA exerts neuroprotection via preventing Aβ-fibril formation, acting as an anti-inflammatory agent, and inhibiting free radical generation and acetylcholinesterase (AChE) enzyme activity. In this review, we present key biological roles of FA and several FA derivatives in preventing Aβ-induced neurotoxicity, protecting against free radical attacks, and exhibiting enzyme inhibitions and evaluate them as possible therapeutic agents for the treatment of AD.
AB - Alzheimer's Disease (AD) is one of the most important neurodegenerative diseases, ac-counting for 60% of all dementia cases. AD is a progressive neurodegenerative disease that occurs due to the production of β-amyloid (Aβ) protein and accumulation of hyper-phosphorylated tau pro-tein; it causes breakage in the synaptic bonds and neuronal deaths to a large extent. Millions of people worldwide suffer from AD because there is no definitive drug for disease prevention, treatment, or slowing down its progression. Over the last decade, multiple target applications have been devel-oped for AD treatments. These targets include Aβ accumulations, hyper-phosphorylated tau pro-teins, mitochondrial dysfunction, and oxidative stress, resulting in toxicity. Various natural or semisynthetic antioxidant formulations have been shown to protect brain cells from Aβ-induced toxicity and provide promising potentials for AD treatment. Ferulic acid (FA), a high-capacity an-tioxidant molecule, is naturally synthesized from certain plants. FA has been shown to have different substantial biological properties, such as anticancer, antidiabetic, antimicrobial, anti-inflamma-tory, hepatoprotective, and cardioprotective actions, etc. Furthermore, FA exerts neuroprotection via preventing Aβ-fibril formation, acting as an anti-inflammatory agent, and inhibiting free radical generation and acetylcholinesterase (AChE) enzyme activity. In this review, we present key biological roles of FA and several FA derivatives in preventing Aβ-induced neurotoxicity, protecting against free radical attacks, and exhibiting enzyme inhibitions and evaluate them as possible therapeutic agents for the treatment of AD.
KW - Alzheimer’s disease
KW - amyloid-beta
KW - anti-Alzheimer
KW - drug candidate
KW - experimental Alzheimer’s model
KW - Ferulic acid
KW - neuroprotection
KW - neurotoxicity
UR - http://www.scopus.com/inward/record.url?scp=85132452734&partnerID=8YFLogxK
U2 - 10.2174/1567201819666211228153801
DO - 10.2174/1567201819666211228153801
M3 - Review article
C2 - 34963433
AN - SCOPUS:85132452734
SN - 1567-2018
VL - 19
SP - 860
EP - 873
JO - Current Drug Delivery
JF - Current Drug Delivery
IS - 8
ER -